



## International Alliance of Dermatology Patient Organizations

GLOBALSKIN.ORG

April 3, 2025

WHO Expert Committee on Selection and Use of Essential Medicines  
World Health Organization  
Geneva, Switzerland

Re: I.1 Public comment new indication of psoriasis: Adalimumab

Dear Members of the WHO Expert Committee,

I am writing on behalf of the International Alliance of Dermatology Patient Organizations (GlobalSkin) to state our support for the expanded recognition of adalimumab in the WHO Essential Medicines List (EML) for the treatment of psoriasis and other immune-mediated conditions (Application I.1). Our organization is an alliance of more than 300 patient organizations across 74 countries representing the full spectrum of skin diseases, including psoriasis.

As one of the most well-studied biologics, adalimumab has transformed the management of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and other autoimmune conditions. Its proven efficacy, long-term safety, and broad clinical use make it an indispensable treatment worldwide. The availability of biosimilars has further improved affordability and access, making adalimumab a cost-effective option for healthcare systems in both high- and low-resource settings.

Psoriasis is a debilitating condition that affects 2-3% of the global population, often leading to significant physical and psychological burden, yet the EML has not been updated for psoriasis in 8 years and only offers methotrexate as a systemic option. Access to biologic therapies such as adalimumab is crucial for patients with moderate-to-severe disease, particularly where conventional treatments have failed. Extending indication for adalimumab to the treatment of psoriasis in the WHO EML would facilitate greater treatment accessibility, improved patient outcomes, and reduced disease burden on healthcare systems.

We commend WHO's commitment to expanding access to essential medicines and urge the Expert Committee to support adalimumab as a cornerstone therapy for immune-mediated diseases, including psoriasis. Thank you for your attention to this important matter, and please do not hesitate to contact us for any additional insights.

Sincerely,

Jennifer Austin  
Chief Executive Officer